Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-26-002470

Chief Scientific Officer sold 6,567 shares at $30.05 ($197,338)

  • Chief Scientific Officer acquired 18,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Bredt David Chief Scientific Officer 2025-12-31 Grant or award −18,000 410,642 D: show line 1 in the form
Bredt David Chief Scientific Officer 2025-12-31 Sale −6,567 $30.05 $197,338 404,075 D: show line 2 in the form
Open-market sales · 6,567 sh · avg $30.05 · $197,338
Loading xslF345X05/ownership.xml…